Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
ADAMTS17 Biologics Sequence Review Report 2026: A disintegrin and metalloproteinase with thrombospondin motifs 17 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADAMTS17 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ADAMTS14 Biologics Sequence Review Report 2026: A disintegrin and metalloproteinase with thrombospondin motifs 14 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADAMTS14 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ADAMTS13 Biologics Sequence Review Report 2026: A disintegrin and metalloproteinase with thrombospondin motifs 13 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADAMTS13 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ADAM22 Biologics Sequence Review Report 2026: Disintegrin and metalloproteinase domain-containing protein 22 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADAM22 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ADAMTS1 Biologics Sequence Review Report 2026: A disintegrin and metalloproteinase with thrombospondin motifs 1 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADAMTS1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ADAMTS10 Biologics Sequence Review Report 2026: A disintegrin and metalloproteinase with thrombospondin motifs 10 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADAMTS10 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
TREM1 Biologics Sequence Review Report 2026: Triggering receptor expressed on myeloid cells 1 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of TREM1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ADAM19 Biologics Sequence Review Report 2026: Disintegrin and metalloproteinase domain-containing protein 19 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADAM19 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
TREM2 Biologics Sequence Review Report 2026: Triggering receptor expressed on myeloid cells 2 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of TREM2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ADAM12 Biologics Sequence Review Report 2026: Disintegrin and metalloproteinase domain-containing protein 12 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADAM12 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
TNFAIP8L2 Biologics Sequence Review Report 2026: Tumor necrosis factor alpha-induced protein 8-like protein 2 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of TNFAIP8L2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
TNFAIP8L1 Biologics Sequence Review Report 2026: Tumor necrosis factor alpha-induced protein 8-like protein 1 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of TNFAIP8L1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.